BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/15/2023 12:44:08 AM | Browse: 384 | Download: 1481
 |
Received |
|
2022-11-20 10:36 |
|
Peer-Review Started |
|
2022-11-20 10:36 |
|
First Decision by Editorial Office Director |
|
2022-12-14 13:56 |
|
Return for Revision |
|
2022-12-14 13:56 |
|
Revised |
|
2022-12-21 13:15 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-12-30 03:28 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-12-31 05:35 |
|
Articles in Press |
|
2022-12-31 05:35 |
|
Edit the Manuscript by Language Editor |
|
2023-01-07 03:32 |
|
Typeset the Manuscript |
|
2023-02-07 06:47 |
|
Publish the Manuscript Online |
|
2023-02-15 00:44 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
Potent bromodomain and extraterminal domain inhibitor JAB-8263 suppresses MYC expression and exerts anti-tumor activity in colorectal cancer models
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xin-Mo Liu, Shao-You Xia, Wei Long, Hai-Jun Li, Gui-Qun Yang, Wen Sun, Song-Yan Li and Xiao-Hui Du |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
81871317 |
|
| Corresponding Author |
Xiao-Hui Du, MD, Chief Doctor, Deputy Director, Professor, Department of General Surgery, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing 100039, China. duxiaohuiplagh@sina.com |
| Key Words |
Bromodomain; Bromodomain and extraterminal domain inhibitor; Colorectal cancer; JAB-8263; MYC; p21 |
| Core Tip |
Treating with the bromodomain and extraterminal domain (BET) inhibitor JAB-8263, we found that MC38 cells undergo cell cycle arrest and apoptosis. In multiple human colorectal cancer cell lines, we found that JAB-8263 can down-regulate c-MYC expression and up-regulate p21 and p16 expression, associated with highly potent antiproliferative effects of JAB-8263 on colorectal cancer (CRC) cells. The conclusions obtained from in vitro experiments were verified in tumor mouse models that JAB-8263 effectively inhibits CRC growth with acceptable tolerance. Our studies suggested that BET can be a potential effective drug target for suppressing CRC growth, and BET inhibitor JAB-8263 can effectively suppress c-MYC expression and exert anti-tumor activity in CRC models. |
| Publish Date |
2023-02-15 00:44 |
| Citation |
Liu XM, Xia SY, Long W, Li HJ, Yang GQ, Sun W, Li SY, Du XH. Potent bromodomain and extraterminal domain inhibitor JAB-8263 suppresses MYC expression and exerts anti-tumor activity in colorectal cancer models. World J Gastrointest Oncol 2023; 15(2): 332-342 |
| URL |
https://www.wjgnet.com/1948-5204/full/v15/i2/332.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v15.i2.332 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
